'Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say' - Reuters

https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/

Why Is Merck Stock Falling Tuesday?

Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet primary endpoints. Read the update.

FDA Approves Merck's IDVYNSO For HIV-1 Infection Treatment In Adult Patients

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk

FDA court freeze leaves COVID, flu, RSV vaccines in limbo as Kennedy's ACIP overhaul faces legal challenge.

Merck Announces Results From Phase 3 LITESPARK-012 Trial Evaluating Combination Regimens For First-Line Treatment Of Patients With Advanced Clear Cell Renal Cell Carcinoma

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with

Merck Announces FDA Priority Review for KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Padcev, For The Treatment Of Patients With Muscle-Invasive Bladder Cancer, With PDUFA Date Set For

If approved, these indications would expand the use of KEYTRUDA and KEYTRUDA QLEX, each in combination with Padcev, as the first perioperative treatments for patients with MIBC regardless of cisplatin eligibility and

7 Health Care Stocks Whale Activity In Today's Session

Merck Says EC Approves ENFLONSIA For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Newborns And Infants

ENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosingMerck (NYSE:MRK), known as MSD outside of the United States and Canada,

Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles

Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and mixed analyst views weigh on outlook.

UBS Maintains Buy on Merck & Co, Raises Price Target to $145

UBS analyst Michael Yee maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $130 to $145.